Loading...
DOCUMENTS
20
NOTICES
33
MOTS CLES
Inflammatory bowel diseases
Maintenance therapy
HIV
Cancer
Clinical trial
Biomarker
Microbiote
Inflammatory bowel disease
Screening
Disease Progression
Gènes
Safety
Vedolizumab
Consensus
IL23
Gene methylation
IL12
Disease progression
RISK
CARCINOGENESIS
Effectiveness
Endoscopic treatment
Kidney diseases
Immunosuppressant
Bacteria
Anti-TNF
Gene expression
DNA methylation
Over 80s
Patient-reported outcome
Patients experience
Algorithm
Immune cells
Upper gastrointestinal tract
Therapeutics
Helicobacter pylori
Rituximab
Ustekinumab
Neoadjuvant chemotherapy
Heart disease risk factors
Anti-TNF agents
IBD
Colorectal cancer Colibactin and lipids
Fecal microbiota
Contraindication
Inflammatory Bowel Diseases
Inclusion
Disability
Survival
Cost effectiveness
Monitoring
Methylation
Drug
Alkylating agents
Dysbiosis
Tailored therapy
Méthylation
MORTALITY
Microbiota
Original Article Clinical
Colorectal cancer
18 FDG-PET/CT
Dysbiose
Thérapie ciblée
Colon cancer
T1118 translocation
Ulcerative colitis
Rituximab plus chlorambucil
Clinical guidelines
Intestinal crypts
Surgery
MICROBIOTA
Tuberculosis
Eradication
Eligibility
COLON-CANCER
Cell adhesion
Epigenetics
Parvimonas micra
Genes
Crohn's disease
Primary sclerosing cholangitis
MALT
Acceptability
Epigénétiques
Bactéries
Small molecules
Resistance
Colon
Colonic epithelial primary cells
MARKER
Crohn’s disease
Résistance
Biologics
Colectomy
DNA METHYLATION
Venous thromboembolism
PCR
Inhibitor
Stricture
Early detection of Colon Cancer using Molecular Markers and Microbiota , EA 7375 | |
---|---|
Institutions |
UPEC |
Adresse |
Université Paris-Est Créteil Groupe Hospitalier Henri Mondor Service de Gastroentérologie 51 Av Maréchal de Lattre de Tassigny 94010 Créteil cedex |
Courriel |
|
Site Internet |
|
Rattachement(s) |
|
Direction |
Aurélien AMIOT |
Adjoint |
Iradj SOBHANI |
Axe(s) de recherche
|
Le laboratoire axe ses recherches sur le rôle du microbiome intestinal ainsi que des changements épigénétiques dans l'intestin afin :
|